New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Learn more about whether Alvotech or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

These findings support the view that the over-functioning iEOS leads to inflammation ... CRSwNP patients is a promising biomarker predicting the 2-year post-operative nasal polyp recurrence (5).

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Following results from their new retrospective study, the researchers suggested that immediate reconstruction of the nose ...